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Challenges facing age-management/longevity medicine
Prior to the discovery of penicillin and production of antibiotics, extrinsic disease was 
the greatest threat to achieving maximum life potential (longevity). That single event 
increased life-span several decades for the majority of people living in ﬁ  rst world 
nations. However, protection against lethal infection provided by antibiotics exposed 
older humans to a wide variety of life-threatening diseases resulting from disintegra-
tion of internal order during senescence. These intrinsic diseases including diabetes, 
stroke, heart attack, cancer, and a multitude of others, resulted in creation of medical 
subspecialties. Although each specialty focused upon different organs and systems, they 
all administered treatment in response to disease. In other words, the operative model 
for modern medicine which deals with intrinsic disease is the same as that which was 
used for extrinsic disease, ie, a disease occurs and then it is treated. However, unlike 
therapy for infection which generally cures disease, treatment of intrinsic diseases only 
provides symptomatic relief, rarely affecting the underlying causes. Also, because it 
targets speciﬁ  c symptoms, this approach treats the disease condition as an isolated 
entity, independent of other bodily functions. Thus, the cardiologist, neurologist, 
allergist, and dermatologist focus their attentions only upon problems occurring within 
the system(s) limited by their training. Accordingly, they prescribe drugs that were 
created to speciﬁ  cally suppress or relieve symptoms directly related to the problem(s). 
Despite the fact that this approach rarely provides a cure, it is effective in extending 
life, if not necessarily its quality, because many of the symptoms of intrinsic disease 
such as extremely high blood pressure, severe hyperglycemia, or profound breathing 
difﬁ  culties can lead to fatal complications.
The pharmaceutical industry ﬁ  ts well within the disease model for medical practice. 
This is because advances in cellular biology and biochemistry allow medicinal chemists 
to design compounds capable of modulating receptor, enzyme, and other molecular 
functions that block or attenuate the symptoms of underlying disease. Generally these 
effects are accompanied by secondary and unintended metabolic consequences. How-
ever, if the net result of administering the compound is to relieve primary symptoms 
then a simple and measurable indicator of efﬁ  cacy has been achieved and a new drug 
is born. In other words, the pharmaceutical industry embraces the disease-oriented 
approach to medical practice because it provides a simple and unambiguous measure 
of efﬁ  cacy for their products.
With continuing research into the consequences of aging, it is becoming appar-
ent that medical practice must evolve from this disease-oriented model to one that 
is health-directed so as to ensure quality of life with longevity. In this alternative 
approach, patient health and vitality is prolonged and onset of intrinsic disease(s) 
is delayed or even prevented well into old age. Although this approach is currently 
being employed by practitioners around the world, it is widely opposed by many in the 
traditional medical community and especially by the pharmaceutical industry. This is 
true for several reasons which include the following:
1.  To sustain optimal health during aging, integrated functions of interdependent 
physiological systems must be preserved as much as possible. This is a very dif-
ﬁ  cult task since temporal, quantitative, and qualitative signaling between these 
functional elements is impossible to simulate perfectly using current technology. 
Richard F Walker
International Society for Applied 
Research in Aging (SARA)Clinical Interventions in Aging 2007:2(2) 176
Walker
2.  A holistic approach to medicine blurs the line between 
specialties since it requires consideration of the entire body 
and its interrelated functions rather than single systems in 
isolation. This requirement tends to diminish a specialists 
expertise and thus is unacceptable to some, and 
3.  Effective interventions that delay or prevent consequences 
of aging are not easily demonstrated because rather than 
simply reducing the intensity of preexisting symptoms as 
is required in the disease-oriented model, proof under the 
health-oriented model requires that efﬁ  cacy be demon-
strated by the absence or delay in onset of symptoms. This 
is a negative proof that requires large numbers of subjects 
and extended periods of observation to achieve.
As a result, it is not surprising to ﬁ  nd that practitioners 
committed to their individual specialty approach to patient 
care are not willing to accept change. Since many of the 
practitioners of “anti-aging” medicine have little or no clas-
sical specialty training, they are often considered unquali-
ﬁ  ed to offer therapies that are the domain of specialists. A 
relevant example is the dispensing of hormones by those 
not boarded in endocrinology. Similarly, pharmaceutical 
companies that see mandates for change in current medical 
practice as a threat to their “bottom lines” strongly object 
to these changes. 
Another problem facing change to health orientation of 
medical practice is that it has been sensationalized by the popu-
lar media as offering the “fountain of youth”. Understandably, 
this type of publicity, coupled with the activities of unscrupu-
lous entrepreneurs seeking to capitalize upon public demand 
for longevity, caused the emerging ﬁ  eld to be tainted. 
Despite these problems, there is a sound basis for seeking 
interventions in aging that have the potential for successful 
clinical application. The most relevant of these are studies 
performed in animals showing that enhancement of neural and 
endocrine functions increase population life span presumably 
by reducing the incidence of age-related, intrinsic disease. 
(Cotzias et al 1974; Walker et al 1988; Besson et al 2003). 
However, the existence of such support for clinical application 
of age-management/longevity therapies has not blunted the 
resolve of those with vested interest in the status quo to block 
change in medical practice. In fact, their efforts have been 
strengthened to some degree the actions of several internet and 
compounding pharmacies that were involved in unprofessional 
and illegal activities. The owners of those “businesses” were 
recently indicted for subverting the doctor-patient relationship 
through illegal sale of steroids and bio-identical hormones 
purportedly for “anti-aging” purposes. (Leusner et al 2007; 
O’Keeffe and Quinn 2007).
The primary approach taken by those who wish to block 
change in medical practice has been to legally challenge the 
safety of compounded prescriptions used by practitioners of 
age management/longevity medicine. Their basic argument is 
that because bio-identical hormones have not passed scrutiny 
of double-blinded, placebo testing and have not been approved 
by FDA under a new drug application (NDA), they may 
be unsafe. The argument is somewhat weak because these 
products have been used for many years without any indication 
of public harm. Also, the complainants fail to acknowledge that 
FDA approval under a NDA does not guarantee safety. In fact, 
some of the drugs that have been approved for use by the FDA 
have been reported to have much more severe side effects than 
any for bio-identical hormones. Some of these include severe 
heart disease attributed to Vioxx and neurological disorders 
associated with the use of “statins” and many other FDA-
approved drugs (Ray et al 2002; Medications.com 2007).
Furthermore, several FDA-approved drugs have 
been reported to cause secondary or iatrogenic diseases. 
Interestingly, these diseases that presumably resulted from 
side effects of the primary drug have led to development 
of new drugs to treat their symptoms thereby expanding 
pharmaceutical sales. For example, Requip is being widely 
marketed to treat restless leg syndrome which has been 
associated with the use of Lipitor (www.medications.com). 
Lipitor is a “statin” drug that inhibits the production of 
cholesterol which is essential for many bodily functions. 
By indiscriminately inhibiting cholesterol synthesis in the 
nervous system, Lipitor may indirectly cause membrane 
degeneration and contribute to adverse neuromuscular prob-
lems. Reports of these relationships have begun appearing 
in peer-reviewed medical journals, and numerous people 
have reported similar symptoms at public adverse effect 
reporting websites such as www.medications.com. These 
report such problems as “trouble swallowing, trouble talking 
and enunciating words, feeling constant fatigue, neck aches, 
motor neuropathy which mimics ALS, blinding headaches, 
nausea, vertigo, disorientation, memory loss, extremely 
dry eyes, pain/stiffness in the neck and calf muscles and 
abdominal pain.” Also, as shown in the Women’s Health 
Initiative, synthetic hormones such as medroxyprogesterone 
that may be more potent than its bio-identical analogue don’t 
necessarily have the same spectrum of actions. As a result, 
it has the potential to cause side effects through interactions 
with other hormones that would not otherwise occur with the 
natural progesterone (Nilsen and Brinton 2003).
These untoward side effects can be explained by the 
fact that drugs are produced to relieve isolated symptoms Clinical Interventions in Aging 2007:2(2) 177
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or to produce speciﬁ  c effects. Thus, their actions on other 
essential aspects of bodily function are largely ignored and 
at best minimized since they are not part of the disease ori-
entation model. 
Finally, a disincentive for pharmaceutical companies to 
run expensive clinical trials involving products commonly 
used in prescription compounding for age-management medi-
cine is that they are not patent protected. Thus, no company 
would expend their resources to meet efﬁ  cacy and safety 
standards knowing that their competitors would simply use 
the same generic product without concern for ownership 
infringement or violation.
In summary, because recognized training programs for 
practitioners of longevity medicine do not exist; because of 
the excessive time, effort and expense required to achieve 
negative proof for therapeutic interventions in aging, 
ie, ones in which treatment prevents or delays onset of 
intrinsic disease; and because protection of investments for 
proving that bio-identical hormone replacement or similar 
interventions in aging prolong health and vitality is lacking, 
the evolution of medical practice from a disease to health 
orientation will not occur as a smooth transition. Rather, it 
will slowly struggle for acceptance under the earlier model 
of common usage.  Indeed, there are active assaults against 
this transition such as the Safe Compounding Drug Act of 
2007 proposed by Senators Kennedy (D/MA) Burr (R/NC) 
and Roberts (R/KS). Under the guise of protecting public 
safety, the legislation would severely restrict and possibly 
totally block access of practitioners and their patients to 
effective compounds for extending health and vitality 
during aging. While there are organized efforts to prevent 
these assaults, the burden of facilitating and expediting the 
process of change in medical practice falls largely upon the 
practitioners themselves who must report relevant ﬁ  ndings 
to the medical community at large as part of the legitimizing 
process. Recognizing that many practitioners may not be 
familiar with the process of writing manuscripts for peer-
review in professional journals nor have the time to devote to 
that task, I suggest a more appropriate alternative. As editor 
of Clinical Interventions in Aging, I urge all practitioners to 
observe and record outcomes of their treatments. Then these 
data should be submitted to the Editor as brief descriptions 
and be included with personal clinical experiences, opinions, 
outcomes (favorable or adverse), simple case reports, letters, 
questions, or comments. The contributions will be edited 
and published in future volumes of the Journal. Although 
the section in which these reports are to be published will 
not necessarily meet peer-review criteria, it will serve as a 
forum for information exchange between practitioners of 
age management/longevity medicine and perhaps contribute 
signiﬁ  cantly to improving attitudes in support of the changing 
focus of medical practice from that of disease treatment to 
health maintenance. In addition, I encourage all who feel that 
such evolution is important and worth supporting to join the 
Society for Applied Research in Aging. Become active in its 
programs for lobbying regulatory agencies to legitimize the 
ﬁ  eld of age-management/longevity medicine so that others 
may view our professional objectives in a favorable light.
References
Besson A, Salemi S, Gallati S, et al. 2003. Reduced longevity in untreated 
patients with isolated growth hormone deﬁ  ciency. J Clin Endocrinol 
Metab, 88:3664–7. 
Cotzias GC, Miller ST, Nicholson AR, et al. 1974. Prolongation of the 
life-span in mice adapted to large amounts of L-dopa. Proc Nat Acad 
Sci U S A, 71:2466–9. 
Leusner J, Gutierrez PR, Lundy S. 2007. Steroid raids net 4 in Orlando. 
Orlando Sentinel, February 28, 2007. 
Medications.com. 2007. Internet search: “Medications contributing to 
restless leg syndrome” [online]. Accessed on May 4, 2007. URL: 
http://www.medications.com. 
Nilsen J, Brinton RD. 2003. Divergent impact of progesterone and medroxy-
progesterone acetate (Proveera) on nuclear mitogen-activated protein 
kinase. PNAS, 100:10506–11. 
O’Keeffe M, Quinn TJ. 2007. ‘Mother lode’ seized from Brooklyn phar-
macy. New York Daily News, May 10, 2007. 
Ray WA, MacDonald TM, Solomon DH, et al. 2002. COX-2 selective 
non-steroidal anti-inﬂ  ammatory drugs and cardiovascular disease. 
Pharmacoepidemiol Drug Saf, 12:67–70. 
Walker RF, Weideman CA, Wheeldon EB. 1988. Reduced disease in aged 
rats treated chronically with ibopamine, a catecholaminergic drug. 
Neurobiol Aging, 9:291–301. 